NVS novartis.com: Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Novartis AG is systematically implementing "green chemistry" and renewable energy into its production. The EV/EBITDA ratio trajectory demonstrates local dynamics, with the metric fixed at 15.33. The success of its transformation into an innovator is based on FDA approvals and patent protection, while a strong talent pool is supported by cutting-edge laboratories and a developed culture of mentorship.

Novartis Corporation - Nilai perusahaan marang bathi operasional sadurunge panyusutan NVS (periode 23.11.2025 - 11.11.2026)

novartis.com - rincian analitis lan metrik utama (NVS)

- rega pasar lan target rega analis:

Bagan rega Novartis Inc.|NVS - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Nilai pasar Novartis Pharma|NVS - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Novartis|NVS - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku novartis.com|NVS - Gunggung Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas Novartis AG|NVS - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Novartis|NVS - Tanggungan utang total perusahaan|Rasio utang marang kapitalisasi buku Novartis Pharma|NVS - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Novartis|Indikator likuiditas cepet novartis.com

- rincian asil keuangan lan kelipatan valuasi:

NVS - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Novartis AG|NVS - Pangali P/E|Rega marang bathi mangsa ngarep Novartis AG|NVS - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Novartis Pharma|NVS - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Novartis|NVS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan novartis.com|NVS - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Novartis AG

Analisis dhasar perusahaan:NVS (Novartis Inc.)

EV/EBITDA serves as a fundamental benchmark for determining the fair value of assets while accounting for debt load and tax obligations. This metric compares the total enterprise value of a business with its operating profit before depreciation and amortization, eliminating the influence of capital structure. By analyzing the EV/EBITDA multiple, an investor assesses the risk of overpaying for an asset. This is critical for Novartis AG (NVS), as the ultra-high margins of gene therapy must justify the market value of this behemoth.

Analisis pesaing Novartis AG